34 results about "Low molecular weight dextran" patented technology

The present invention discloses a molded article containing high molecular weight α-1,4-glucan and/or its modification, and low molecular weight α-1,4-glucan and/or its modification. The low molecular weight α-1,4-glucan has the degree of polymerization of greater than or equal to 180 and less than 620. And the high molecular weight α-1,4-glucan has the degree of polymerization of greater than or equal to 620 and less than 37000. The high molecular weight α-1,4-glucan may preferably have a molecular weight distribution of not greater than 1.25, and the low molecular weight α-1,4-glucan may preferably have a molecular weight distribution of not greater than 1.25. The present invention also discloses a process for preparing the molded article, wherein the process comprises the step of adding the low molecular weight α-1,4-glucan and/or its modification to a solution comprising the high molecular weight α-1,4-glucan and/or its modification to gel the solution.

The invention discloses a preparation method and a use of low-molecular weight beta-glucan and belongs to the technical field of food and beverage processing. The preparation method comprises the following steps of preparing an aqueous solution having a mass concentration of 1-5% from marketed food-grade cereal beta-glucan, carrying out treatment by endo-type beta-glucanase for 0.5-4h, controlling viscosity (2%, <100cp) and molecular weight (of 10-100KDa), carrying out decoloring by active carbon, collecting beta-glucan having the molecular weight of 10-100KDa by an ultrafilter membrane, and carrying out freeze drying to obtain a product. The low-molecular weight beta-glucan can be used in foods such as beer and beverages, improves daily intake of beta-glucan, improves human immunity and reduces cholesterol.

The invention discloses a method for preparing medium-low molecular weight dextran by using a biological method. The method comprises the following steps: adding a leuconostoc mesenteroides seed solution in a fermentation medium containing sucrose for carrying out fermentation culture; then adding a penicillium cyclopium seed solution or fermentation broth supernate of the penicillium cyclopium for continuously fermenting and culturing; and separating dextran from the fermentation broth to obtain the medium-low molecular weight dextran. The invention further discloses the prepared dextran and application thereof. The invention provides a method for directly obtaining the medium-low molecular weight dextran by using the biological method in a mode of coupling fermentation of double microorganisms. The medium-low molecular weight dextran is synthesized by directionally regulating and controlling through the biological method, so that the generated dextran degrades to form dextran which tends to be required by clinical application. Meanwhile, according to the method disclosed by the invention, ethanol precipitation can be directly carried out, and thus redundant, time-consuming and noble gradual dividing precipitation is omitted, the yield of the dextran is increased, and the use amount and the consumption of ethanol are reduced.

The invention discloses a preparation method of an adenosine triphosphate coenzyme insulin freeze-dried powder injection, comprising the following steps of: adjusting injection water with diluted hydrochloric acid until the pH value is 2.5-3.5, adding insulin and uniformly mixing to obtain a solution I; adding L-arginine and disodium ethylene diamine tetraacetate in the injection water, uniformlystirring, adding carbon and stirring; after removing carbon, adding adenosine disodium triphosphate and uniformly stirring to obtain a solution II; adding calcium gluconate, low molecular weight dextran and cysteine hydrochloride in the injection water, adding carbon and removing the carbon and uniformly stirring to obtain a solution III; mixing three solutions, uniformly stirring, adjusting the pH value to be 5.7-6.2 with a 2-4 percent NaOH solution, adding coenzyme A and supplementing the balance of injection water; and sterilizing, measuring the content, subpackaging and freezing dry. The adenosine triphosphate coenzyme insulin freeze-dried powder injection prepared by the method has the advantages of favorable redissolution, clearness and quality stability of products and is saturatedin appearance.

The troxerutin powder for injection includes troxerutin 2-100 wt% and excipient 0-98 wt%, and the excipient is one of mannitol, lactose, glycine, sorbic alcohol, low molecular weight dextran, glucose, cane sugar and hydrolysate gel. It is bacteria-free powder or bacteria-free freeze dried produce. The present invention is used in treating ischemic cerebral vascular diseases, central retinitis, arteriosclerosis, thrombotic phlebitis, varicosity, etc. and has the advantages of stability, fast dissolution in water and high safety.

The present invention relates to a methylergometrine maleate powder injection, which pertains to the field of pharmaceutical preparations; the present invention contains the methylergometrine maleate which is taken as the active ingredient and the pharmaceutically acceptable carriers, wherein, the weight ratio of the methylergometrine maleate and the pharmaceutically acceptable carriers is 1: 15 to 1: 300, the pharmaceutically acceptable carriers are one or more of the lactose, glucose, mannitol, low molecular weight dextran, sodium chloride and aminoacetic acid. The present invention also provides a preparation method of methylergometrine maleate powder injection. The powder injection of the present invention has good stability, easy storage and transportation, furthermore, the irritation is significantly decreased and the compliance of the patients is increased.

The invention discloses a preparation method of iron-dextrin. The preparation method comprises the following steps: preparing low molecular weight dextran through bi-enzyme (dextransucrase-dextranase) synergy, and then oxidizing dextran by taking sodium hypochlorite mixed liquor as an oxidizing agent, so as to obtain an oxidation-type dextran; simultaneously titrating and complexing with weak base and acid-base to prepare iron-dextrin and curing iron-dextrin under the conditions of high temperature and high pH value, so as to obtain cured iron-dextrin; filtering unreacted dextran and micromolecule iron-dextrin and ions therein with biological membranes with different molecular weights, so as to obtain purified iron-dextrin. The iron-dextrin prepared by the invention is uniform in distribution of the molecular weight, high in stability and less in content of impurities. Various indexes of iron-dextrin synthesized by the method conform to the requirements of Chinese pharmacopoeia, and the solubility of iron-dextrin is very good.

The present invention discloses a one-step fermentation production method for low molecular weight dextran. The production process comprises the following steps: inoculating Leuconostoc mesenteroides into a sucrose culture medium, and carrying out fermentation for 16-24 h to synthesize a fermentation liquid containing a dextran crude product; adding dextran enzyme to the fermentation liquid until a final dextran enzyme concentration is 0.05-5 U/mL, continuously carrying out fermentation, and carrying out the reaction for 2-8 h; after completing the reaction, carrying out inactivation to obtain a dextran crude product fermentation liquid; and carrying out a post-treatment on the crude product fermentation liquid to obtain the dextran finished product. Compared with traditional methods, the production process of the present invention has advantages of low technology difficulty, simple equipment, process simplification, and good control of low molecular weight dextran synthesis.

The invention discloses a low-molecular-weight glucan, characterized in that the glucan is obtained by separating from radix astragali. The invention also discloses a method for separating and purifying the low-molecular-weight glucan. In addition, the invention discloses a use of the low-molecular-weight glucan in the preparation of a medicament for the immunopotentiation and the adjutant therapyof tumor or a health food.

The invention discloses cryopreserving liquid for cryopreserving a single karyocyte. The cryopreserving liquid is prepared from fetal bovine serum, dimethyl sulfoxide and dextran dissolving liquid, wherein the fetal bovine serum accounts for 45 to 95 percent; the dextran dissolving liquid accounts for 10 to 50 percent; the dimethyl sulfoxide accounts for 5 to 10 percent. Dextran refers to low-molecular-weight dextran; a molecular weight of the dextran is 40,000. The cryopreserving liquid uses the low-molecular-weight dextran to replace part of animal serum, and can be used for effectively reducing an introduction amount of foreign protein. The cryopreserving liquid provided by the invention can be used for effectively retaining the cell activity of the single karyocyte which is directly cryopreserved after being extracted. If the single karyocyte is subjected to recovery culture at an interval after being subjected to cryopreservation treatment by using the cryopreserving liquid provided by the invention, a cell recovery rate can be maintained at a higher level, and further, the cell differentiation capacity is still high.

The invention discloses a cell freezing medium. The cell freezing medium is prepared from the following components in percentage by volume and by concentration: 2 to 8 percent of dimethyl sulfoxide, 0.5 to 1.5 mg/ml of pawpaw extracting solution, 2.0 to 5mg/ml of chitosan quaternary ammonium salt, 0.5 to 2 percent of low molecular weight dextran, 8 to 15 percent of human serum albumin, 1.0 to 5mg/ml of glucan and the balance of DMEM culture medium. According to the cell freezing medium disclosed by the invention, the chitosan quaternary ammonium salt, the glucan and the pawpaw extracting solution are added, so that the limitation that chitosan can be only dissolved in a weak acid solution can be overcome; in addition, the effect of the cell freezing medium is better; by means of the glucan, the extracellular osmotic pressure can be improved and intracellular free water is reduced; due to the adoption of a permeable protective agent DMSO, cell rupture can be prevented, the melting pointof the intracellular water is reduced, and the formation of crystals is prevented; the permeable protective agent complements with a non-permeable protective agent glucan and the chitosan quaternaryammonium salt, so as to realize synergistic effects. The pawpaw extracting solution is a novel efficient natural antioxidant substance which is extracted from pawpaw and cannot be synthesized in a human body. The pawpaw extracting solution mainly plays an antioxidant role, and has the effects of improving cellular immune functions and prolonging cell activity.

The invention provides a preparation method and application of dextriferron with a weight average molecular weight between 1500 and 4000 Da. Specifically, maltose and sucrose are used as substrates, alow molecular weight dextran solution is prepared by complexing the maltose and sucrose with ferric trichloride under the action of dextransucrase, and a dextriferron solution is used to prepare a low molecular weight dextriferron injection. According to the preparation method of the invention, the conventional macromolecular degradation method is replaced with a small molecule polymerization manner to prepare the low molecular weight dextriferron injection, the cheap maltose and sucrose are used as the substrates, so that the preparation cost is low; moreover, by adjusting the ratio of the substrates, i.e., maltose and sucrose, dextriferron with different sugar chain lengths is prepared; a complex catalyst is introduced into the complexation process of iron to improve the complexation efficiency; the obtained low molecular weight dextran injection has the advantages of small irritancy, good absorption and iron supplementation effect and the like, and can be used as a preferred iron supplement agent for pigs, cattle, sheep and other livestock.

The invention discloses a low-molecular-weight glucan, characterized in that the glucan is obtained by separating from radix astragali. The invention also discloses a method for separating and purifying the low-molecular-weight glucan. In addition, the invention discloses a use of the low-molecular-weight glucan in the preparation of a medicament for the immunopotentiation and the adjutant therapyof tumor or a health food.

Methods, and related products and compositions, of increasing the stability of a Bayer process liquor are described. A method of increasing the stability of a Bayer process liquor includes contacting the Bayer process liquor with a ppm quantity of a low molecular weight dextran. Also described are methods, and related products and compositions, for controlling the precipitation of aluminium-containing compounds from a Bayer process liquor.

The invention belongs to the technical field of medicine, and discloses a drug composition of ligustrazine hydrochloride and benzyl alcohol and a preparation method thereof. The weight ratio of the ligustrazine hydrochloride and the benzyl alcohol is 1:0.01 to 0.1, and an injection is prepared by the drug composition and pharmaceutically acceptable excipients; and the excipients are selected from one or more of mannitol, sorbitol, low-molecular-weight dextran or sodium chloride. The drug composition can be used for treating cerebral vascular diseases, overcomes the defects that the ligustrazine hydrochloride injection has greater irritation in the process of clinical administration in the prior art, and is favorable for expanding clinical medication.

The invention discloses a method for accurately regulating and controlling alpha-glucan enzymolysis reaction and directionally extracting a specific molecular weight product and application of the method, and belongs to the technical field of biochemical separation. Glucan is not only a polymer capable of forming a phase body, but also the molecular weight of glucan is a key factor influencing a phase forming condition, and the final target molecular weight of the enzymolysis reaction falls on a phase splitting point by adjusting the phase body composition of other high polymers. And meanwhile, the high partition coefficient of the alpha-glucanase in part of the polymer phase is utilized to quickly recover enzyme protein from the reaction phase and stop the enzymolysis reaction, and after the low-molecular-weight alpha-glucan is separated, the enzyme is recovered again through a specific concentrated salt solution which is compatible with the alpha-glucanase protein.